 Daxor Corporation NYSE MKT: DXR an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today filed a Form N-CSR disclosing its schedule of portfolio holdings as of December 31, 2019. For the third straight year on a double-digit pace, Daxor reported that kit sales rose over 7 year-on-year in the cardiology segment 22.7 excluding a supplier disruption in q4 of 2019, driven by increasing awareness of the value of blood volume analysis to improve heart failure outcomes through reduced mortality and readmissions, as well as five new hospital systems under contract. In addition, Daxor successfully completed its first SBIR with the DOD for the procurement of blood volume analyzers and looks forward to subsequent government contracts. 